Trial Profile
Immunomodulation and Multiple Sclerosis Epidemiology
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Oct 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMSE
- 29 Sep 2009 New trial record
- 10 Sep 2009 One year results have been presented at ECTRIMS 2009.